project: cardiodx

CardioDX logo

Connect with a Sales Specialist

x

Repository of Clinical Trial Samples

CardioDx actively conducts prospective clinical research studies in the area of cardiovascular medicine. Patient blood samples are collected and may be analyzed using multiple "omics" approaches, including genomics (genetics and gene expression), proteomics and metabolomics. The aim of these studies is to drive the discovery of molecular signals that can help identify the risk and presence (or absence) of predefined disease states, including obstructive* CAD and arrhythmia.

Sample Collection and Patient Selection

CardioDx has collected peripheral blood samples (for DNA and RNA) in three prospective clinical studies: PREDICT, COMPASS and DISCERN. Plasma samples were also collected in the PREDICT and DISCERN studies.

PREDICT (NCT00500617) - The purpose of the PREDICT study was to develop and validate a diagnostic blood assay for obstructive coronary artery disease (CAD). The study population included stable chest pain patients undergoing clinically indicated invasive coronary angiography or coronary CT angiography.

COMPASS (NCT01117506) - The purpose of the COMPASS study was to determine the accuracy of Corus® CAD in identifying the likelihood of obstructive CAD in a nondiabetic patient population (with chest pain) who have been referred to a clinically indicated myocardial profusion stress test (nuclear stress test).

DISCERN (NCT00500708) - The aim of the DISCERN study was to identify novel genetic and other biological markers that distinguish patients at increased risk for lethal ventricular arrhythmias. The patient population included patients with ventricular dysfunction (low ejection fraction) with either ICDs or CRT-Ds implanted for primary or secondary prevention.

If you are interested in collaborating with CardioDx or learning more about our repository of clinical trial samples, please contact Jim Wingrove at 650-475-2788.


* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography or coronary computed tomography angiography (≥2.0 mm lumen diameter).